Mcph1/Brit1 deficiency promotes genomic instability and tumor formation in a mouse model

Oncogene

Volumn 34, Issue 33, 2015, Pages 4368-4378

  Liang, Y ^a,b   Gao, H ^a   Lin, S Y ^c   Goss, J A ^a   Du, C ^d   Li, K ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TAISHAN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; MCPH1 PROTEIN, MOUSE; NONHISTONE PROTEIN;

ANEUPLOIDY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CENTROSOME; CHROMOSOME; CHROMOSOME ABERRATION; CHROMOSOME BREAKAGE; CONTROLLED STUDY; DNA END JOINING REPAIR; DNA REPAIR; GENE INACTIVATION; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; MCPH1 GENE; METAPHASE; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; SPECTRAL KARYOTYPING; THYMUS LYMPHOMA; TUMOR SUPPRESSOR GENE; ANIMAL; CELL TRANSFORMATION; DEFICIENCY; DISEASE MODEL; DOUBLE STRANDED DNA BREAK; FIBROBLAST; GENETICS; KNOCKOUT MOUSE; LYMPHOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY;

MURINAE; MUS;

ANEUPLOIDY; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CENTROSOME; CHROMOSOMAL PROTEINS, NON-HISTONE; CHROMOSOME ABERRATIONS; DISEASE MODELS, ANIMAL; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; FIBROBLASTS; GENES, TUMOR SUPPRESSOR; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; LYMPHOMA; MICE; MICE, KNOCKOUT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84939564947     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.367     Document Type: Article

References (66)

1. Rai R, Dai H, Multani AS, Li K, Chin K, Gray J, et al. BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell 2006; 10: 145-157.
2. Lin SY, Liang Y, Li K. Multiple roles of MCPH1/MCPH1 in DNA damage response, DNA repair, and cancer suppression. Yonsei Med J 2010; 51: 295-301.
3. Venkatesh T, Suresh PS. Emerging roles of MCPH1: expedition from primary microcephaly to cancer. Eur J Cell Biol 2014; 93: 98-105.
4. Mohammad DH, Yaffe MB. 14-3-3 proteins, FHA domains and BRCT domains in the DNA damage response. DNA Repair (Amst) 2009; 8: 1009-1017.
5. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J 1997; 11: 68-76.
6. Manke IA, Lowery DM, Nguyen A, Yaffe MB. BRCT repeats as phosphopeptidebinding modules involved in protein targeting. Science 2003; 302: 636-639.
7. Yu X, Chini CC, He M, Mer G, Chen J. The BRCT domain is a phospho-protein binding domain. Science 2003; 302: 639-642.
8. Clapperton JA, Manke IA, Lowery DM, Ho T, Haire LF, Yaffe MB, et al. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol 2004; 11: 512-518.
9. Wood JL, Singh N, Mer G, Chen J. MCPH1 functions in an H2AX-dependent but MDC1-independent pathway in response to DNA damage. J Biol Chem 2007; 282: 35416-35423.
10. Yang SZ, Lin FT, Lin WC. MCPH1/MCPH1 cooperates with E2F1 in the activation of checkpoint, DNA repair and apoptosis. EMBO Rep 2008; 9: 907-915.
11. Peng G, Yim EK, Dai H, Jackson AP, Burgt I, Pan MR, et al. MCPH1/MCPH1 links chromatin remodelling to DNA damage response. Nat Cell Biol 2009; 11: 865-872.
12. Wu X, Mondal G, Wang X, Wu J, Yang L, Pankratz VS, et al. Microcephalin regulates BRCA2 and Rad51-associated DNA double-strand break repair. Cancer Res 2009; 69: 5531-5536.
13. Leung JW, Leitch A, Wood JL, Shaw-Smith C, Metcalfe K, Bicknell LS, et al. SET nuclear oncogene associates with microcephalin/MCPH1 and regulates chromosome condensation. J Biol Chem 2011; 286: 21393-21400.
14. Gruber R, Zhou Z, Sukchev M, Joerss T, Frappart PO, Wang ZQ. MCPH1 regulates the neuroprogenitor division mode by coupling the centrosomal cycle with mitotic entry through the Chk1-Cdc25 pathway. Nat Cell Biol 2011; 13: 1325-1334.
15. Singh N, Wiltshire TD, Thompson JR, Mer G, Couch FJ. Molecular basis for the association of microcephalin (MCPH1) protein with the cell division cycle protein (Cdc27) subunit of the anaphase-promoting complex. J Biol Chem 2012; 287: 2854-2862.
16. Shi L, Li M, Su B. MCPH1/MCPH1 represses transcription of the human telomerase reverse transcriptase gene. Gene 2012; 495: 1-9.
17. Liang Y, Gao H, Lin SY, Peng G, Huang X, Zhang P, et al. MCPH1/MCPH1 is essential for mitotic and meiotic recombination DNA repair and maintaining genomic stability in mice. PLoS Genet 2010; 6: e1000826.
18. Alderton GK, Galbiati L, Griffith E, Surinya KH, Neitzel H, Jackson AP, et al. Regulation of mitotic entry by microcephalin and its overlap with ATR signalling. Nat Cell Biol 2006; 8: 725-733.
19. Brown JA, Bourke E, Liptrot C, Dockery P, Morrison CG. MCPH1/MCPH1 limits ionizing radiation-induced centrosome amplification. Oncogene 2010; 29: 5537-5544.
20. Richardson J, Shaaban AM, Kamal M, Alisary R, Walker C, Ellis IO, et al. Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. Breast Cancer Res Treat 2011; 127: 639-648.
21. Brüning-Richardson A, Bond J, Alsiary R, Richardson J, Cairns DA, McCormack L, et al. ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival. Br J Cancer 2011; 104: 1602-1610.
22. Venkatesh T, Nagashri MN, Swamy SS, Mohiyuddin SM, Gopinath KS, Kumar A. Primary microcephaly gene MCPH1 shows signatures of tumor suppressors and is regulated by miR-27a in oral squamous cell carcinoma. PLoS ONE 2013; 8: e54643.
23. Zhang J, Wu XB, Fan JJ, Mai L, Cai W, Li D, et al. MCPH1 protein expression in normal and neoplastic lung tissues. Asian Pac J Cancer Prev 2013; 14: 7295-7300.
24. Bhattacharya N, Mukherjee N, Singh RK, Sinha S, Alam N, Roy A, et al. Frequent alterations of MCPH1 and ATM are associated with primary breast carcinoma: clinical and prognostic implications. Ann Surg Oncol 2013; 20(Suppl 3): S424-S432.
25. Celeste A, Difilippantonio S, Difilippantonio MJ, Fernandez-Capetillo O, Pilch DR, Sedelnikova OA, et al. H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell 2003; 114: 371-383.
26. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006; 12: 440-450.
27. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445: 661-665.
28. Olive PL, Banth JP. The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 2006; 1: 23-29.
29. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. GammaH2AX and cancer. Nat Rev Cancer 2008; 8: 957-967.
30. Ward IM, Difilippantonio S, Minn K, Mueller MD, Molina JR, Yu X, et al. 53BP1 cooperates with p53 and functions as a haploinsufficient tumor suppressor in mice. Mol Cell Biol 2005; 25: 10079-10086.
31. Sung P, Klein H. Mechanism of homologous recombination: mediators and helicases take on regulatory functions. Nat Rev Mol Cell Biol 2006; 7: 739-750.
32. Lieber MR, Ma Y, Pannicke U, Schwarz K. Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 2003; 4: 712-720.
33. Rothenberg EV, Taghon T. Molecular genetics of T cell development. Annu Rev Immunol 2005; 23: 601-649.
34. Matsumoto K, Yoshikai Y, Moroi Y, Asano T, Ando T, Nomoto K. Two differential pathways from double-negative to double-positive thymocytes. Immunology 1991; 72: 20-26.
35. Efeyan A, Serrano M. p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 2007; 6: 1006-1010.
36. Bachelier R, Xu X, Wang X, Li W, Naramura M, Gu H, et al. Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice. Oncogene 2003; 22: 528-537.
37. Kang J, Ferguson D, Song H, Bassing C, Eckersdorff M, Alt FW, et al. Functional interaction of H2AX, NBS1, and p53 in ATM-dependent DNA damage responses and tumor suppression. Mol Cell Biol 2005; 25: 661-670.
38. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007; 9: 166-180.
39. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006; 9: 121-132.
40. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, et al. Genomewide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007; 45: 938-947.
41. Duesberg P, Fabarius A, Hehlmann R. Aneuploidy, the primary cause of the multilateral genomic instability of neoplastic and preneoplastic cells. IUBMB Life 2004; 56: 65-81.
42. Gordon DJ, Resio B, Pellman D. Causes and consequences of aneuploidy in cancer. Nat Rev Genet 2012; 13: 189-203.
43. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, et al. Mutations of mitotic checkpoint genes in human cancers. Nature 1998; 392: 300-303.
44. Tarapore P, Fukasawa K. Loss of p53 and centrosome hyperamplification. Oncogene 2002; 21: 6234-6240.
45. Rai R, Phadnis A, Haralkar S, Badwe RA, Dai H, Li K, et al. Differential regulation of centrosome integrity by DNA damage response proteins. Cell Cycle 2008; 7: 2225-2233.
46. Tibelius A, Marhold J, Zentgraf H, Heilig CE, Neitzel H, Ducommun B, et al. Microcephalin and pericentrin regulate mitotic entry via centrosomeassociated Chk1. J Cell Biol 2009; 185: 1149-1157.
47. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
48. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-792.
49. Wong AK, Ormonde PA, Pero R, Chen Y, Lian L, Salada G, et al. Characterization of a carboxy-terminal BRCA1 interacting protein. Oncogene 1998; 17: 2279-2285.
50. Hiramoto T, Nakanishi T, Sumiyoshi T, Fukuda T, Matsuura S, Tauchi H, et al. Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer. Oncogene 1999; 18: 3422-3426.
51. Schoenmakers EF, Huysmans C, Van de Ven WJ. Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas. Cancer Res 1999; 59: 19-23.
52. Mohaghegh P, Hickson ID. DNA helicase deficiencies associated with cancer predisposition and premature ageing disorders. Hum Mol Genet 2001; 10: 741-746.
53. Guidos CJ, Williams CJ, Grandal I, Knowles G, Huang MT, Danska JS. V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors. Genes Dev 1996; 10: 2038-2054.
54. Nacht M, Strasser A, Chan YR, Harris AW, Schlissel M, Bronson RT, et al. Mutations in the p53 and SCID genes cooperate in tumorigenesis. Genes Dev 1996; 10: 2055-2066.
55. Gurley KE, Vo K, Kemp CJ. DNA double-strand breaks, p53, and apoptosis during lymphomagenesis in scid/scid mice. Cancer Res 1998; 58: 3111-3115.
56. Zhang B, Wang E, Dai H, Hu R, Liang Y, Li K, et al. BRIT1 regulates p53 stability and functions as a tumor suppressor in breast cancer. Carcinogenesis 2013; 34: 2271-2280.
57. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-860.
58. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607-614.
59. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861-872.
60. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
61. Mailloux AW, Young MR.. NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment. J Immunol 2009; 182: 2753-2765.
62. Grundy S, Plumb J, Lea S, Kaur M, Ray D, Singh D. Down regulation of T cell receptor expression in COPD pulmonary CD8 cells. PLoS ONE 2013; 8: e71629.
63. Mei J, Huang X, Zhang P. Securin is not required for cellular viability, but is required for normal growth of mouse embryonic fibroblasts. Curr Biol 2001; 11: 1197-1201.
64. Singh B, Stoffel A, Gogineni SK, Poluri A, Pfister DG, Shaha AR, et al. Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas. Am J Pathol 2002; 161: 365-371.
65. Sotiropoulou PA, Candi A, Mascr G, De Clercq S, Youssef KK, Lapouge G, et al. Bcl-2 and accelerated DNA repair mediates resistance of hair follicle bulge stem cells to DNA-damage-induced cell death. Nat Cell Biol 2010; 12: 572-582.
66. Milliken EL, Lozada KL, Johnson E, Landis MD, Seachrist DD, Whitten I, et al. Ovarian hyperstimulation induces centrosome amplification and aneuploid mammary tumors independently of alterations in p53 in a transgenic mouse model of breast cancer. Oncogene 2008; 27: 1759-1766.